Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19058112 | USE OF EFFECTIVE PART EXTRACT OF MONOCHASMA SAVATIERI IN PREPARATION OF DRUG FOR TREATING INFLAMMATORY DISEASE OR TUMOR | March 2025 | January 2026 | Abandon | 11 | 0 | 1 | No | No |
| 19075007 | METHODS OF TREATING MIGRAINES WITH A COMBINATION OF A MELOXICAM AND A RIZATRIPTAN | March 2025 | November 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 19056358 | CHEMICAL STRUCTURES THAT CONTROL METABOLIC ELIMINATION OF AMINOSTEROLS | February 2025 | October 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18587175 | ORAL GLIPTIN COMPOSITIONS AND METHOD FOR PREPARATION THEREOF | February 2024 | January 2025 | Allow | 11 | 1 | 1 | No | No |
| 18443875 | HYDROCORTISONE ORAL LIQUID FORMULATIONS | February 2024 | December 2024 | Abandon | 10 | 0 | 1 | No | No |
| 18411219 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | January 2024 | February 2026 | Abandon | 25 | 0 | 1 | No | No |
| 18541291 | SUPRAMOLECULAR BIOMEDICAL POLYMERS | December 2023 | December 2025 | Allow | 24 | 2 | 0 | Yes | No |
| 18493090 | QUATERNARY AMMONIUM CYCLODEXTRIN AND PREPARATION METHOD AND USES THEREOF, AND SILVER NANOPARTICLE-CYCLODEXTRIN COMPLEX AND PREPARATION METHOD AND USES THEREOF | October 2023 | December 2024 | Allow | 14 | 2 | 1 | No | No |
| 18556634 | PURIFIED PSYCHOACTIVE ALKALOID EXTRACTION USING ACIDIFIED ACETONE | October 2023 | May 2025 | Abandon | 18 | 1 | 1 | No | No |
| 18481549 | FORMULATIONS OF DAZUCORILANT, A GLUCOCORTICOID RECEPTOR MODULATOR | October 2023 | March 2025 | Allow | 17 | 2 | 1 | Yes | No |
| 18465893 | BUPIVACAINE LIQUID FORMULATIONS | September 2023 | February 2026 | Allow | 29 | 3 | 1 | Yes | No |
| 18239072 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | August 2023 | October 2024 | Abandon | 14 | 2 | 0 | No | No |
| 18340702 | COMPOSITIONS AND METHODS FOR TOPICAL TREATMENT OF VASCULAR CONDITIONS | June 2023 | January 2025 | Abandon | 19 | 3 | 1 | Yes | Yes |
| 18335052 | METHODS OF TREATMENT | June 2023 | March 2026 | Abandon | 33 | 2 | 1 | No | No |
| 18324305 | INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING A CYCLODEXTRIN, A HYDROPHOBIC DRUG, A CO-SOLVENT AND A PRESERVATIVE | May 2023 | February 2026 | Allow | 33 | 1 | 1 | No | No |
| 18322521 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | May 2023 | October 2025 | Abandon | 29 | 0 | 1 | No | No |
| 18310575 | SOLUTIONS FOR ORAL DOSAGE | May 2023 | January 2025 | Allow | 20 | 2 | 1 | Yes | No |
| 18132144 | CONTACT LENS PRODUCT HAVING ANTIOXIDATIVE FUNCTION | April 2023 | October 2025 | Abandon | 30 | 2 | 1 | No | No |
| 18128550 | COMPOSITIONS AND KITS FOR OMEPRAZOLE SUSPENSION | March 2023 | July 2025 | Allow | 28 | 4 | 1 | Yes | No |
| 18026765 | SPECIALIZED PRO-RESOLVING MEDIATORS (SPMs) AS MELANOCYTE GROWTH PROMOTER AND PRO-SURVIVAL FACTORS AND USES THEREOF | March 2023 | September 2024 | Allow | 18 | 2 | 1 | No | No |
| 18184135 | METHODS OF ADMINISTERING AN ARIPIPRAZOLE INJECTABLE PREPARATION | March 2023 | December 2024 | Abandon | 21 | 4 | 1 | Yes | No |
| 18177694 | POLY(ETHYLENE GLYCOL)-BLOCK-POLY(PROPYLENE SULFIDE) NANOCARRIER PLATFORM FOR ENHANCED EFFICACY OF IMMUNOSUPPRESSIVE AGENTS | March 2023 | January 2026 | Abandon | 35 | 2 | 1 | No | No |
| 18115690 | CRILA® AND EGCG COMPOSITIONS FOR TREATMENT OF FIBROIDS | February 2023 | June 2025 | Allow | 27 | 4 | 1 | Yes | No |
| 18075720 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | December 2022 | December 2024 | Abandon | 24 | 0 | 1 | No | No |
| 17963502 | METHODS OF TREATING AND/OR PREVENTING ACTINIC KERATOSIS | October 2022 | January 2026 | Allow | 40 | 1 | 0 | No | No |
| 17995079 | TREATMENT | September 2022 | December 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17914163 | TREATMENT OF RESPIRATORY DISORDERS | September 2022 | November 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17939569 | COSMETIC COMPOSITION FOR PEEL-OFF-TYPE PACKS, AND METHOD FOR PRODUCING SAME | September 2022 | March 2025 | Allow | 30 | 1 | 1 | Yes | No |
| 17903026 | USE OF EFFECTIVE PART EXTRACT OF MONOCHASMA SAVATIERI IN PREPARATION OF DRUG FOR TREATING INFLAMMATORY DISEASE OR TUMOR | September 2022 | November 2024 | Allow | 26 | 1 | 1 | Yes | No |
| 17895809 | ANTI-CANCER EFFECTS OF JAK2 INHIBITORS IN COMBINATION WITH THALIDOMIDE DERIVATIVES AND GLUCOCORTICOIDS | August 2022 | May 2025 | Abandon | 33 | 2 | 1 | No | No |
| 17894265 | PHOTOSENSITISING COMPOSITION AND USES THEREOF | August 2022 | November 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17892782 | PHOSPHOLIPID COMPOSITIONS | August 2022 | November 2024 | Allow | 27 | 1 | 1 | No | No |
| 17889304 | Milrinone Composition and Method for Administering Same | August 2022 | February 2025 | Abandon | 30 | 1 | 1 | No | No |
| 17872921 | FORMULATIONS OF BRINCIDOFOVIR | July 2022 | August 2025 | Allow | 36 | 3 | 1 | Yes | Yes |
| 17851871 | IONIC LIQUIDS FOR INTERNAL DELIVERY | June 2022 | October 2025 | Abandon | 40 | 2 | 1 | No | No |
| 17843031 | 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID AND METHODS OF USE THEREOF | June 2022 | December 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17667909 | MULTI-KINASE INHIBITORS OF VEGF AND TGF BETA AND USES THEREOF | February 2022 | January 2026 | Abandon | 47 | 1 | 1 | No | No |
| 17589012 | METHODS OF TREATING SARIN EXPOSURE WITH TETRAHYDROCANNABINOL AND CANNABIDIOL COMBINATIONS | January 2022 | May 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17618152 | USING PARASYMPATHOMIMETIC DRUGS ALONE OR, IN COMBINATION WITH ONE OR MORE ALPHA AGONISTS IN PSEUDOPHAKIC PATIENTS, TO CREATE MULTI-FOCALITY | December 2021 | May 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17540563 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | December 2021 | April 2025 | Allow | 40 | 2 | 2 | Yes | No |
| 17527025 | HYALURONIC ACID-BASED GELS INCLUDING LIDOCAINE | November 2021 | September 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17493761 | SEED CONGLOMERATION: A DISRUPTIVE INNOVATION TO REDUCE CLEANING REQUIREMENTS OF SMALL SEEDED SPECIES | October 2021 | March 2026 | Abandon | 53 | 1 | 2 | No | No |
| 17602424 | METHODS AND COMPOSITIONS FOR USE IN TREATMENT OF CANCER WITHOUT PSYCHOACTIVE EFFECTS | October 2021 | June 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17594292 | METHODS OF ADMINISTERING AN ARIPIPRAZOLE INJECTABLE PREPARATION | October 2021 | February 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17439136 | Macromolecule-Supported TLR Agonists | September 2021 | May 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17437160 | NOVEL SALTS, CRYSTALLINE FORMS AND PREMIX OF HYPOLIPIDEMIC AGENT | September 2021 | November 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17467795 | METHODS AND COMPOSITIONS FOR REDUCING ALCOHOL TOXICITY | September 2021 | November 2024 | Abandon | 38 | 2 | 1 | Yes | No |
| 17463258 | COMPOSITIONS AND KITS FOR OMEPRAZOLE SUSPENSION | August 2021 | March 2025 | Allow | 43 | 3 | 1 | No | No |
| 17403813 | Method of treating and/or preventing viral infections | August 2021 | September 2025 | Abandon | 49 | 1 | 1 | Yes | No |
| 17310432 | AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | August 2021 | April 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17426882 | SOLID FORMS OF A PROMOTER OF SPINOGENESIS | July 2021 | August 2025 | Allow | 48 | 2 | 1 | No | No |
| 17426896 | IMIDAZOPYRIDINE DERIVATIVE COMPOUNDS AND USE OF SAME | July 2021 | August 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17426281 | DISULPHIDE COMPOUNDS | July 2021 | October 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17426411 | ABRASION-RESISTANT OPIOID FORMULATIONS WHICH RESIST ABUSE AND INCLUDE A SEQUESTERED OPIOID ANTAGONIST | July 2021 | December 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17422397 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | July 2021 | October 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17371585 | PHARMACEUTICAL USE | July 2021 | October 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17311684 | METHODS, COMPOSITIONS AND KITS FOR TREATING MULTIPLE SCLEROSIS AND OTHER DISORDERS | June 2021 | January 2026 | Allow | 56 | 3 | 1 | No | No |
| 17299928 | SYNERGISTIC COMPOSITIONS COMPRISING (R)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE AND (S)-2-(2-e OXOPYRROLEDIN-1-YL)BUTANAMEDE IN A NON-RACEMIC RATIO | June 2021 | October 2025 | Abandon | 52 | 3 | 1 | No | No |
| 17314746 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR, CEREBROVASCULAR AND OTHER VASCULAR DISEASE PATIENTS | May 2021 | November 2025 | Abandon | 54 | 6 | 1 | No | No |
| 17283854 | COMPOSITIONS AND METHODS FOR CONTROLLING PLANT PESTS AND IMPROVING PLANT HEALTH | April 2021 | August 2025 | Abandon | 52 | 0 | 2 | No | No |
| 17279536 | ALPHA-2C ADRENOCEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP RELATED BREATHING DISORDERS | March 2021 | November 2025 | Abandon | 56 | 4 | 1 | No | No |
| 17267938 | MULTI-KINASE INHIBITORS OF VEGF AND TGF BETA AND USES THEREOF | February 2021 | August 2025 | Allow | 54 | 6 | 1 | Yes | No |
| 17255887 | COMPOSITIONS COMPRISING AMINO ACIDS FOR USE IN THE PREVENTION AND TREATMENT OF LIVER DISEASES | December 2020 | November 2024 | Allow | 47 | 2 | 0 | No | No |
| 17252549 | STABILIZED HYALURONIC ACID | December 2020 | July 2025 | Allow | 55 | 2 | 1 | No | No |
| 17120800 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | December 2020 | April 2025 | Abandon | 52 | 1 | 1 | No | No |
| 17048803 | TOPOLOGICAL ADHESION OF MATERIALS | October 2020 | September 2025 | Abandon | 59 | 4 | 0 | Yes | No |
| 17072726 | USE OF ARTEMISININ FOR TREATING TUMORS INDUCED BY ONCOGENIC VIRUSES AND FOR TREATING VIRAL INFECTIONS | October 2020 | July 2024 | Allow | 45 | 2 | 1 | Yes | No |
| 17047155 | NECROPTOSIS INDUCERS OR AUTOPHAGY INHIBITORS OR A COMBINATION THEREOF | October 2020 | March 2025 | Allow | 53 | 2 | 1 | No | No |
| 16971280 | OSTEOCLAST DIFFERENTIATION INHIBITOR CONTAINING UROLITHIN | August 2020 | November 2025 | Abandon | 60 | 4 | 1 | Yes | No |
| 16963219 | OPHTHALMIC COMPOSITIONS COMPRISING BILASTINE, A BETA-CYCLODEXTRIN AND AT LEAST ONE GELLING AGENT | July 2020 | October 2025 | Abandon | 60 | 4 | 1 | Yes | No |
| 16932111 | DERMAL PATCHES AND GLASS SWABS FOR APPLICATION OF TOPICAL IMMUNOSENSITIZERS | July 2020 | December 2022 | Abandon | 29 | 5 | 1 | Yes | Yes |
| 16955221 | SILICONE RESIN-COVERED SILICONE ELASTOMER PARTICLES, ORGANIC RESIN ADDITIVE, AND OTHER USES | June 2020 | September 2024 | Allow | 51 | 3 | 1 | Yes | No |
| 16893903 | PHARMACEUTICAL FORMULATION FOR THE ELIMINATION OF CAUSATIVE AGENTS OF HERPESVIRAL INFECTIONS FROM THE TISSUES OF A MACROORGANISM | June 2020 | November 2024 | Abandon | 54 | 4 | 1 | No | No |
| 16891391 | POLY(ETHYLENE GLYCOL)-BLOCK-POLY (PROPYLENE SULFIDE) NANOCARRIER PLATFORM FOR ENHANCED EFFICACY OF IMMUNOSUPPRESSIVE AGENTS | June 2020 | October 2025 | Abandon | 60 | 5 | 1 | No | No |
| 16879075 | Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same | May 2020 | December 2024 | Allow | 55 | 7 | 1 | Yes | No |
| 15931270 | COMPOSITIONS AND METHODS FOR TREATING KERATINOUS SUBSTRATES | May 2020 | March 2025 | Allow | 58 | 2 | 2 | Yes | No |
| 16761779 | EXTENDED RELEASE FORMULATIONS FOR INTRA-ARTICULAR APPLICATIONS | May 2020 | April 2025 | Allow | 60 | 5 | 1 | No | No |
| 16649268 | Ophthalmic Pharmaceutical Composition, Ophthalmic Kit, and Pharmaceutical Application Thereof | March 2020 | August 2024 | Allow | 53 | 5 | 1 | Yes | No |
| 16645975 | METHODS OF TREATING EPILEPSY OR STATUS EPILEPTICUS | March 2020 | October 2024 | Abandon | 55 | 4 | 1 | No | No |
| 16642620 | Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry Disease | February 2020 | July 2025 | Abandon | 60 | 3 | 1 | No | Yes |
| 16624439 | Method of Treatment of Cancer | December 2019 | May 2025 | Abandon | 60 | 6 | 1 | No | No |
| 16713460 | BENEFIT AGENT CONTAINING DELIVERY PARTICLE | December 2019 | September 2025 | Abandon | 60 | 6 | 1 | No | No |
| 16618779 | LOW-ALCOHOL ANTIMICROBIAL COMPOSITION AND USE THEREOF | December 2019 | January 2025 | Abandon | 60 | 4 | 1 | No | Yes |
| 16486290 | FORMULATIONS OF CANNABINOIDS FOR THE TREATMENT OF DERMATITIS AND INFLAMMATORY SKIN DISEASES | August 2019 | November 2025 | Abandon | 60 | 4 | 1 | No | Yes |
| 16451999 | METHODS OF TREATING SKIN WITH AROMATIC SKIN-ACTIVE INGREDIENTS | June 2019 | December 2024 | Allow | 60 | 3 | 1 | Yes | Yes |
| 16425580 | ANTIMICROBIAL COMPOSITIONS | May 2019 | July 2024 | Allow | 60 | 2 | 0 | Yes | Yes |
| 16224433 | INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING A CYCLODEXTRIN A HYDROPHOBIC DRUG, A CO-SOLVENT, AND A PRESERVATIVE | December 2018 | April 2025 | Allow | 60 | 4 | 1 | No | Yes |
| 16210714 | Extruded Immediate Release Abuse Deterrent Pill | December 2018 | March 2020 | Allow | 15 | 1 | 1 | Yes | No |
| 16084207 | Food Compositions for Weaning | September 2018 | December 2025 | Abandon | 60 | 8 | 0 | No | Yes |
| 16081290 | GLYCOALKALOID COMBINATIONS AND VARIOUS USES THEREOF | August 2018 | March 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 15780320 | A METHOD FOR PREPARATION OF REDUCIBLE DEGRADABLE HYPERBRANCHED POLYMERIC MICELLES | May 2018 | January 2020 | Allow | 19 | 1 | 0 | No | No |
| 15960004 | PHARMACEUTICAL FORMULATIONS OF NITRITE AND USES THEREOF | April 2018 | November 2021 | Abandon | 42 | 2 | 1 | Yes | Yes |
| 15728196 | COMPOSITIONS, METHODS OF MAKING A COMPOSITION, AND METHODS OF USE | October 2017 | August 2025 | Abandon | 60 | 8 | 1 | Yes | No |
| 15538828 | NANOPARTICLES AND THEIR USE IN CANCER THERAPY | June 2017 | March 2020 | Allow | 32 | 3 | 2 | Yes | No |
| 15505897 | METHODS AND REAGENTS FOR PREVENTION AND/OR TREATMENT OF INFECTION | February 2017 | January 2026 | Abandon | 60 | 11 | 0 | Yes | Yes |
| 15332805 | Cyclic Peptidomimetic Compounds as Immunomodulators | October 2016 | February 2018 | Allow | 16 | 0 | 1 | Yes | No |
| 15228674 | 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | August 2016 | July 2019 | Allow | 35 | 2 | 1 | No | No |
| 15115479 | OIL-IN -WATER EMULSION SUNSCREEN COMPOSITION | July 2016 | October 2024 | Allow | 60 | 10 | 0 | No | Yes |
| 14386160 | COMPOSITIONS AND METHODS FOR REGULATING HAIR GROWTH | September 2014 | September 2025 | Abandon | 60 | 13 | 1 | No | Yes |
| 14457714 | EXTRUDED IMMEDIATE RELEASE ABUSE DETERRENT PILL | August 2014 | November 2018 | Allow | 51 | 10 | 1 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner THOMAS, TIMOTHY P.
With a 40.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner THOMAS, TIMOTHY P works in Art Unit 1614 and has examined 187 patent applications in our dataset. With an allowance rate of 20.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.
Examiner THOMAS, TIMOTHY P's allowance rate of 20.9% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by THOMAS, TIMOTHY P receive 2.14 office actions before reaching final disposition. This places the examiner in the 58% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by THOMAS, TIMOTHY P is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +44.8% benefit to allowance rate for applications examined by THOMAS, TIMOTHY P. This interview benefit is in the 90% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 11.6% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 11.3% of cases where such amendments are filed. This entry rate is in the 11% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 47.4% of appeals filed. This is in the 13% percentile among all examiners. Of these withdrawals, 33.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.2% of allowed cases (in the 80% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.1% of allowed cases (in the 81% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.